5HT2aRは,AHR経路を調節することにより,肺動脈高血圧に寄与する
Xiaoxuan Lu1, Huiyuan Hu2, Yuying Liu1
1State Key Laboratory of Respiratory Health and Multimorbidity, Department of Physiology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing 100005, China.
Biochemical pharmacology
|August 30, 2025
まとめ
肺動脈高血圧 (PAH) は重篤な肺疾患である. ネズミのセロトニン2A受容体 (5-HT2aR) を阻害することで,PAHの症状と炎症が軽減され,新たな治療標的となる可能性を示唆した.
科学分野:
- 心血管研究
- 肺医学
- 分子生物学
背景:
- 肺動脈高血圧 (PAH) は肺血管の改造を伴う.
- セロトニン2A受容体 (5-HT2aR) は,PAHの病原性に関与しています.
- 関連するラットモデルにおける5-HT2aR欠乏症の役割は不明である.
研究 の 目的:
- ネズミの実験用PAHに対する5-HT2aR欠乏の影響を調査する.
- PAHにおける5-HT2aRの役割の基礎となるメカニズムを解明する.
- 5HT2aRをPAHの潜在的な治療標的として評価する.
主な方法:
- CRISPR/Cas9を使って Htr2a ノックアウトラットを生成した.
- モノクロタリン (MCT) またはSU5416/低酸素 (SU/Hx) を用いた確立されたPAHモデル
- 評価されたPAHフェノタイプと,RNA配列とqPCRによる肺組織遺伝子発現の分析.
主要な成果:
- Htr2a欠乏症は,MCTおよびSU/Hx誘発モデルの両方でPAH現象を著しく弱めた.
- 右心室内静脈圧の低下,高縮,肺動脈小動脈の中央壁の厚さが見られた.
- アリル炭化水素受容体 (AHR) 経路標的 (Cyp1a1,Cyp1b1,Ahrr) のダウンレギュレーションがノックアウトラットで明らかになった.
結論:
- 5-HT2aRの損失は,実験的なPAHをラットモデルで軽減する.
- AHR経路に関連する遺伝子発現の抑制は潜在的なメカニズムです.
- 5-HT2aR抑制は,PAHの治療戦略として有望である.
関連する概念動画
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
223
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
223
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
253
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
253
01:30Pulmonary Hypertension: Classification and Pathogenesis
284
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
284
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
911
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
911
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
251
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
251
01:31Adrenergic Receptors: ɑ Subtype
1.7K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.7K